John Sinclair, PhD, DABT, is a seasoned professional in the fields of pharmacology, toxicology, and regulatory affairs, currently engaged in nonclinical development at Kodiak Sciences, focusing on novel therapeutics for ophthalmic diseases since 2018. Prior experience includes roles at BioMarin Pharmaceutical Inc., where John contributed to the development of biopharmaceuticals for rare diseases, and the FDA, where John served as a regulatory pharmacologist and toxicologist for ophthalmic products. Additional positions include neuroscience research and program development at ABA Consulting, investigative pharmacologist at Allergan, research scientist at Acucela Inc., and research associate at Novartis. Academic credentials include a Ph.D. in Neuroscience from UCLA and a Bachelor of Science in Chemistry and Pharmacology from Stony Brook University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices